摘要
目的:探讨重组人干扰素α-2b阴道泡腾胶囊联合苦参凝胶治疗宫颈人乳头瘤病毒亚临床感染的疗效及安全性。方法:宫颈HPV亚临床感染患者74例随机分为观察组(n=37例)和对照组(n=37例)。观察组患者予以重组人干扰素α-2b阴道泡腾胶囊联合苦参凝胶治疗;对照组患者单纯予重组人干扰素α-2b阴道泡腾胶囊治疗。连续3个疗程后,观察两组患者的临床疗效及不良反应,并比较随访观察治疗后6个月的临床疗效。结果:治疗3个疗程后,观察组临床总有效率明显高于对照组(P<0.05);两组均未发生严重药物不良反应,两组不良反应发生率比较差异不明显(P>0.05)。治疗后随访6个月,观察组临床总有效率明显高于对照组(P<0.05)。结论:重组人干扰素a-2b阴道泡腾胶囊联合苦参凝胶治疗宫颈HPV亚临床感染的疗效确切,安全性较佳,远期疗效较肯定。
Objective: To discuss the curative effect and security of recombinant human interferon α-2b vaginal effervescent capsules combined with matrine gels in the treatment of cervical human papilloma virus( HPV) subclinical infection. Methods:Totally 74 cases of patients with cervical HPV subclinical infection were selected and divided into the observation group( n = 37)and the control group( n = 37) at random. The patients in the observation group were given recombinant human interferon α-2b vaginal effervescent capsules combined with matrine gels,while the patients in the control group were only given recombinant human interferon α-2b vaginal effervescent capsules for 3 treatment courses. The clinical curative effect and adverse reactions in the two groups after the medical treatment were observed,and the clinical curative effect in the 6-month follow-up after the medical treatment was observed and compared. Results: After the 3-month treatment,the total clinical efficiency in the observation group was much higher than that in the control group( P〈0. 05). There was no severe adverse drug reaction( ADR) appeared in the two groups and the incidence of ADR in the two groups showed no significant difference( P〉0. 05). Six-month follow-up was performed and the total clinical efficiency in the observation group was much higher than that in the control group( P〈0. 05).Conclusion: Recombinant human interferon α-2b vaginal effervescent capsules combined with matrine gels have reliable curative effect on cervical HPV subclinical infection with high security and reliable long-term follow-up efficacy,which is benefit for the reoccurrence control of the disease.
出处
《中国药师》
CAS
2014年第12期2095-2097,共3页
China Pharmacist
关键词
宫颈人乳头瘤病毒
亚临床感染
重组干扰素α-2b栓
苦参凝胶
Cervical human papilloma virus(HPV)
Subclinical infection
Recombinant human interferon α-2b vaginal effervescent capsules
Matrine gels